After stock slides, Amgen addresses bone density talk on obesity drug
A lot of Amgen’s future rides on its experimental obesity medicine MariTide. At least in the minds of investors.
Ahead of the biopharma’s most critical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
